Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms

Biochemical Pharmacology

Volumn 71, Issue 4, 2006, Pages 521-529

  Zhang, Jean Y ^a   Kowal, Dianne M ^a   Nawoschik, Stanley P ^a   Lou, Zhuangwei ^a   Dunlop, John ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT2 receptors; 5 HT2C isoforms; Antipsychotics; Aripiprazole; Functional activity; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; NEUROLEPTIC AGENT; OLANZAPINE; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR;

ANIMAL CELL; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CALCIUM; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTRACELLULAR SPACE; PIPERAZINES; PROTEIN ISOFORMS; QUINOLONES; RECEPTOR, SEROTONIN, 5-HT2C; RNA EDITING; SEROTONIN UPTAKE INHIBITORS; TRANSFECTION;

EID: 30444450710     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.11.007     Document Type: Article

References (34)

1. G.F. Busatto, and R.W. Kerwin Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia J Psychopharmacol 11 1997 3 12
2. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 1999 106S 115S
3. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog Neuro-Psychopharmacol Biol Psychiatry 27 2003 1159 1172
4. D.M. Taylor Aripiprazole: a review of its pharmacology and clinical use Int J Clin Pract 57 2003 49 51
5. 2 receptor agonist antipsychotic Expert Opin Investig Drugs 12 2003 655 662
6. V. Ozdemir, J. Fourie, and F. Ozdener Aripiprazole Curr Opin Investig Drugs 3 2002 113 120
7. 2 receptor antagonistic activity J Pharmacol Exp Ther 274 1995 329 336
8. S.G. Potkin, A.R. Saha, M.J. Kujawa, W.H. Carson, M. Ali, and E. Stock Aripiprazole, an antipsychotic with a novel mechanism of action, and resperidone vs. placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 2003 681 690
9. M.J. Millan Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors J Pharmacol Exp Ther 295 2000 853 861
10. 1A receptor Eur J Pharmacol 441 2002 137 140
11. M.L. Crismon, A. Deleon, and A.L. Miller Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? Ann Pharmacother 37 2003 738 740
12. K.D. Burris, T.F. Molski, and C. Xu Aripiprazole a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 2002 381 389
13. G. Gründer, A. Carlsson, and D.F. Wong Mechanism of new antipsychotic medications, occupancy is not just antagonism Arch Gen Psychiatry 60 2003 974 977
14. K. Aihara, J. Shimada, T. Miwa, K. Tottori, K.D. Burris, and F.D. Yocca The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release Brain Res. 1003 2004 9 17
15. J.L. Petrie, A.R. Saha, and J.P. McEvoy Aripiprazole, a new atypical antipsychotic: phase II clinical trial results Eur Neuropsychopharmacol 7 1997 S227
16. J. Kane, and G. Ingenito Activity of aripiprazole in psychotic disorders: comparison with haloperidol and placebo Int J Neuropsychopharmacol 3 2000 S124
17. R.M. Bowles, and G.M. Levin Aripiprazole: a new atypical antipsychotic drug Ann Pharmacother 37 2003 687 694
18. D.A. Shapiro, S. Renock, E. Arrington, L.A. Chiodo, L.X. Liu, and D.R. Sibley Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 2003 1400 1411
19. 2 receptor subtypes: a family re-united Trends Pharmacol Sci 16 1995 105 109
20. 2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum Neuropsychopharmacology 26 2002 311 324
21. V. Di Matteo, M. Cacchio, C. Di Giulio, and E. Esposito Role of serotonin2C receptors in the control of brain dopaminergic function Pharmacol Biochem Behav 71 2002 727 734
22. K. Herrick-Davis, E. Grinde, and M. Teitler Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors J Pharmacol Exp Ther 295 1998 226 232
23. L. Rauser, J.E. Savage, H.Y. Meltzer, and B.L. Roth Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine (2C) receptor J Pharmacol Exp Ther 299 1 2001 83 89
24. 2C receptor is reduced in schizophrenia Mol Psychiatry 6 2001 373 379
25. 2C receptors and their possible relevance to antimigraine efficacy Br J Pharmacol 140 2003 277 284
26. J.M. Launay, P. Herve, K. Peoch, C. Tournois, and J. Callebert Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension Nat Med 8 2002 1129 1135
27. 2B receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro Br J Pharmacol 135 2002 1144 1151
28. E. Richelson Receptor pharmacology of neuroleptics: relation to clinical effects J Clin Psychiatry 60 1999 5 14
29. S.P. Vickers, P.G. Clifton, C.T. Dourish, and L.H. Tecott Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice Psychopharmacology (Berl) 143 1999 309 314
30. 2C receptor selective agonist with anorectic activity J Pharmacol Exp Ther 313 2005 862 869
31. D.B. Allison, J.L. Mentore, and M. Heo Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 11 1999 1686 1696
32. G. Di Giovanni, V. Di Matteo, M. Di Mascio, and E. Esposito Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study Synapse 35 2000 53 61
33. L.W. Fitzgerald, G. Lyer, D.S. Conklin, and C.M. Krause Messenger RNA editing of the human serotonin 5-HT2C receptor Neuropsychopharmacology 21 1999 82S 90S
34. i values J Pharmacol Exp Ther 251 1989 238 246